Skip to main content

Table 1 Clinical characteristics of patients with MCTD

From: Association study between immune-related miRNAs and mixed connective tissue disease

MCTD
Clinical parameters N* Mean values ± SD or n** (%)
Demographic characteristics Age 100 43.43 ± 13.77471
Gender (n = female) 100 84 (84%)
Disease activity Disease duration [months] 100 148.2 ± 272.6612
Damage index 100 9.79 ± 13.547
The course of disease Single phase 100 12 (12%)
Multiphase 28 (28%)
Progressive 60 (60%)
Autoantibody profile Anti-U1 RNP 100 99 (99%)
Anti-U1 RNP 70 100 75 (75%)
A 100 83 (83%)
C 100 79 (79%)
Anti-CCP 71 3 (4.22%)
Anti-ANA 99 98 (98.98%)
Anti-SmB 100 31 (31%)
Anti-SmD 100 6 (6%)
Anti-Ro 60 100 10 (10%)
Anti-Ro 52 100 24 (24%)
Anti-La 100 2 (2%)
Anti-Rib P 100 3 (3%)
Anti-PCNA 100 1 (1%)
Anti-CENP B 100 0
Anti-Scl-70 100 2 (2%)
Anti-Jo-1 100 1 (1%)
Anti-His 100 15 (15%)
Anti-DNA 100 13 (13%)
RF 98 36 (36.73%)
Clinical manifestation SLE-like skin lesions 100 71 (71%)
Ocular lesions 99 60 (60.60%)
Cardiomyopathy 100 4 (4%)
Dysphagia 100 22 (22%)
Deforming or erosive arthritis 100 12 (13%)
Poikiloderma 100 31 (31%)
Raynaud syndrome 100 97 (97%)
Sjögren’s syndrome 69 22 (31.88%)
Swollen fingers or hands 100 92 (92%)
Polyarthritis 100 94 (94%)
Lymphadenopathy 100 26 (26%)
Facial erythema 100 43 (43%)
Pericarditis/pleuritis 100 16 (16%)
Leukopenia/thrombocytopenia 100 65 (65%)
Scleroderma 100 34 (34%)
Pulmonary fibrosis 100 31 (31%)
Esophageal disorders 100 23 (23%)
Myopathy 100 66 (66%)
  1. RF rheumatoid factor, CCP anti-CCP antibodies, U1 RNP anti-U1RNP antibodies, ANA antinuclear antibodies, 70 anti-U1 70 kDa antibodies, A anti-U1 A antibodies, C anti-U1 C antibodies, SmB anti-Sjögren’s syndrome type B antibodies, SmD anti-SmD antibody, Ro 60 anti-Ro-60 antibody, Ro 52 anti-Ro52 antibody, La antibody to the La antigen, Rib P anti-ribosomal P protein antibody, PCNA anti-PCNA antibody, CENP B anti-CENP-B antibody, Scl-70 anti-Scl-70 antibodies, Jo-1 anti-Jo-1 antibody, His anti-histone antibody, DNA anti-dsDNA antibody
  2. *N, number of patients with clinical information
  3. **n, number of patients with positive clinical manifestation